$36.38 Million in Sales Expected for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) This Quarter

Brokerages forecast that Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) will announce sales of $36.38 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Karyopharm Therapeutics’ earnings. The highest sales estimate is $38.14 million and the lowest is $34.26 million. Karyopharm Therapeutics posted sales of $22.60 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 61%. The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Karyopharm Therapeutics will report full year sales of $164.20 million for the current year, with estimates ranging from $143.92 million to $182.78 million. For the next year, analysts forecast that the company will post sales of $193.85 million, with estimates ranging from $162.36 million to $238.77 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Karyopharm Therapeutics.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.10. During the same period last year, the company earned ($0.77) EPS.

Several research analysts recently issued reports on the company. StockNews.com started coverage on Karyopharm Therapeutics in a research report on Thursday, March 31st. They set a “hold” rating for the company. Royal Bank of Canada cut their price target on Karyopharm Therapeutics from $12.00 to $8.00 and set a “sector perform” rating for the company in a report on Tuesday, March 8th. Canaccord Genuity Group cut their price target on Karyopharm Therapeutics from $20.00 to $10.00 in a report on Monday, April 11th. JPMorgan Chase & Co. upgraded Karyopharm Therapeutics from an “underweight” rating to a “neutral” rating and set a $8.00 price target for the company in a report on Wednesday, February 9th. Finally, SVB Leerink cut their price target on Karyopharm Therapeutics from $8.00 to $6.00 and set a “market perform” rating for the company in a report on Wednesday, March 2nd. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $11.57.

Shares of Karyopharm Therapeutics stock opened at $5.21 on Thursday. Karyopharm Therapeutics has a 1 year low of $4.42 and a 1 year high of $14.73. The company has a market capitalization of $413.77 million, a P/E ratio of -3.54 and a beta of -0.16. The business has a 50 day moving average price of $6.94 and a 200 day moving average price of $7.63.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Aaron Wealth Advisors LLC purchased a new stake in Karyopharm Therapeutics during the 1st quarter worth $385,000. Marshall Wace LLP purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth $57,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Karyopharm Therapeutics by 78.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,641 shares of the company’s stock worth $78,000 after purchasing an additional 4,664 shares during the period. Point72 Hong Kong Ltd purchased a new position in Karyopharm Therapeutics in the 3rd quarter valued at about $63,000. Finally, American Trust purchased a new position in Karyopharm Therapeutics in the 4th quarter valued at about $81,000. 67.75% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile (Get Rating)

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.

See Also